X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (93) 93
female (75) 75
oncology (66) 66
adult (54) 54
middle aged (54) 54
aged (47) 47
index medicus (36) 36
ovarian neoplasms - drug therapy (31) 31
cancer (29) 29
male (28) 28
aged, 80 and over (27) 27
ovarian cancer (24) 24
obstetrics & gynecology (22) 22
treatment outcome (21) 21
care and treatment (20) 20
chemotherapy (20) 20
hematology, oncology and palliative medicine (18) 18
ovarian neoplasms - pathology (18) 18
article (16) 16
disease-free survival (16) 16
drug administration schedule (16) 16
obstetrics and gynecology (16) 16
antibodies, monoclonal - therapeutic use (15) 15
antineoplastic agents - therapeutic use (15) 15
peritoneal neoplasms - drug therapy (15) 15
research (15) 15
trial (15) 15
clinical trials (14) 14
neoplasm recurrence, local - drug therapy (14) 14
therapy (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
dose-response relationship, drug (13) 13
gynecologic-oncology-group (13) 13
paclitaxel (13) 13
radioimmunotherapy (13) 13
antibodies, monoclonal - adverse effects (12) 12
neoplasms, glandular and epithelial - drug therapy (12) 12
carcinoma (11) 11
cisplatin (11) 11
expression (11) 11
antineoplastic agents - adverse effects (10) 10
carcinoma, ovarian epithelial (10) 10
yttrium radioisotopes - therapeutic use (10) 10
breast-cancer (9) 9
combined modality therapy (9) 9
neoplasm staging (9) 9
neoplasms - drug therapy (9) 9
oncology, experimental (9) 9
ovarian neoplasms - metabolism (9) 9
paclitaxel - administration & dosage (9) 9
adolescent (8) 8
antibodies, monoclonal - administration & dosage (8) 8
antimitotic agents (8) 8
antineoplastic agents (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
carboplatin - administration & dosage (8) 8
drug resistance, neoplasm (8) 8
lymphoma, non-hodgkin - radiotherapy (8) 8
recurrence (8) 8
rituximab (8) 8
analysis (7) 7
antineoplastic agents - administration & dosage (7) 7
bevacizumab (7) 7
cell line, tumor (7) 7
diseases (7) 7
endometrial cancer (7) 7
phase-ii trial (7) 7
survival rate (7) 7
antibodies, monoclonal, humanized (6) 6
antigens, cd20 - immunology (6) 6
antineoplastic agents - pharmacokinetics (6) 6
antineoplastic agents - pharmacology (6) 6
carboplatin (6) 6
disease progression (6) 6
epidermal-growth-factor (6) 6
hematology (6) 6
hematopoietic stem cell transplantation (6) 6
immunohistochemistry (6) 6
low-grade (6) 6
metastatic colorectal-cancer (6) 6
ovarian neoplasms - enzymology (6) 6
ovarian neoplasms - genetics (6) 6
pegylated liposomal doxorubicin (6) 6
peritoneal neoplasms - pathology (6) 6
pharmacology & pharmacy (6) 6
product development (6) 6
prognosis (6) 6
relapse (6) 6
survival (6) 6
survival analysis (6) 6
tumors (6) 6
animals (5) 5
apoptosis - drug effects (5) 5
biomarkers, tumor - metabolism (5) 5
cell lung-cancer (5) 5
cervical cancer (5) 5
cetuximab (5) 5
combination (5) 5
endometrial neoplasms - drug therapy (5) 5
factor receptor (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, ISSN 0165-5876, 07/2016, Volume 86, pp. 250 - 255
Objectives: To develop consensus recommendations for pen-operative tracheotomy care in pediatric patients. Methods: Expert opinion by the members of the... 
OTORHINOLARYNGOLOGY | Tracheostomy | PEDIATRICS | Tracheotomy | Pediatric
Journal Article
International Journal of Women's Health, ISSN 1179-1411, 2014, Volume 6, Issue 1, pp. 149 - 157
Fallopian tube carcinoma (FTC) is considered a rare malignancy, but recent evidence shows that its incidence may have been underestimated. Risk-reducing... 
Fallopian tube carcinoma | Serous tubal intraepithelial carcinomas | High grade serous cancers | Care and treatment | Diagnosis | Risk factors | Ovarian cancer | Proteins | Cysts | Pathogenesis | Genes | Biomarkers | Oncology | Mutation | Phosphatase | Kinases | Deoxyribonucleic acid--DNA | Tumors
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 11/2015, Volume 14, Issue 11, pp. 2569 - 2575
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2009, Volume 15, Issue 17, pp. 5404 - 5413
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. TPS3131 - TPS3131
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e18157 - e18157
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 2506 - 2506
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2015, Volume 10, Issue 12, p. e0144126
Molecular targeted therapies have been the focus of recent clinical trials for the treatment of patients with recurrent epithelial ovarian cancer (EOC). The... 
CX-4945 | TYROSINE KINASE | MULTIDISCIPLINARY SCIENCES | PROTEIN-KINASE CK2 | RESISTANCE | FALLOPIAN-TUBE | SRC FAMILY KINASES | CELL-LINES | INHIBITOR | EXPRESSION | CHRONIC MYELOID-LEUKEMIA | Proto-Oncogene Proteins c-vav - antagonists & inhibitors | Dystroglycans - antagonists & inhibitors | Gene Library | Humans | Casein Kinase II - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols | Neoplasms, Glandular and Epithelial - metabolism | Dasatinib - pharmacology | Drug Synergism | GRB2 Adaptor Protein - antagonists & inhibitors | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Cell Line, Tumor | Protein Kinase C-epsilon - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Ovarian Neoplasms - metabolism | Ovarian Neoplasms - drug therapy | Naphthyridines - pharmacology | Apoptosis | RNA, Small Interfering - metabolism | Proteins | Tyrosine | Care and treatment | Genes | Libraries | Genetic engineering | Gene expression | Cancer | Ovarian cancer | Protein kinase C | Target recognition | Disease | Lethality | Casein kinase II | Cancer therapies | Genetic screening | Signal transduction | Catalysis | Protein-tyrosine kinase | Bioinformatics | Drug dosages | Enzymes | Medical research | Sensitivity analysis | Bioavailability | Patients | Survival | Gene silencing | Screening | Pathology | Inhibitors | Biomarkers | Cell proliferation | Phosphorylation | Ovarian carcinoma | Laboratories | Clinical trials | Biology | Genomes | Kinases | Synergism | Rodents | Epidermal growth factor receptors | siRNA | ErbB-2 protein | Grb2 protein | Medicine | Sensitivity | Scaffolding | Cell lines | Response rates | Tumors
Journal Article
BioMed Research International, ISSN 2314-6133, 2015, Volume 2015, p. 341723
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 09/2017, Volume 146, Issue 3, pp. 484 - 490
Indoleamine 2,3-dioxygenase-1 (IDO1) is a key regulator of immune tolerance in ovarian cancer. This study investigated efficacy and safety of the IDO1 enzyme... 
Epacadostat | IDO1 enzyme inhibitor | Tamoxifen | Ca-125 | Ovarian cancer | SURVIVAL | DIAGNOSIS | PROTEIN | PROGNOSIS | INDOLEAMINE 2,3-DIOXYGENASE | OBSTETRICS & GYNECOLOGY | ONCOLOGY | IMMUNOTHERAPY | EXPRESSION | T-CELLS | Recurrence | Neoplasms, Glandular and Epithelial - chemistry | Oximes - pharmacokinetics | Oximes - adverse effects | Peritoneal Neoplasms - blood | Humans | Middle Aged | Oximes - therapeutic use | Response Evaluation Criteria in Solid Tumors | Fatigue - chemically induced | Peritoneal Neoplasms - chemistry | Antineoplastic Agents, Hormonal - adverse effects | Early Termination of Clinical Trials | Fallopian Tube Neoplasms - blood | Neoplasms, Glandular and Epithelial - blood | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - chemistry | Exanthema - chemically induced | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Ovarian Neoplasms - drug therapy | Pruritus - chemically induced | Fallopian Tube Neoplasms - drug therapy | Drug Eruptions - etiology | Ovarian Neoplasms - chemistry | CA-125 Antigen - blood | Indoleamine-Pyrrole 2,3,-Dioxygenase - analysis | Ovarian Neoplasms - blood | Survival Rate | Sulfonamides - pharmacokinetics | Disease-Free Survival | Sulfonamides - therapeutic use | Tamoxifen - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Sulfonamides - adverse effects | Aged | Tamoxifen - adverse effects | Indoleamine-Pyrrole 2,3,-Dioxygenase - antagonists & inhibitors | Care and treatment | Chemotherapy | Enzyme inhibitors | Cancer | Medical research | Medicine, Experimental
Journal Article
Oncogene, ISSN 0950-9232, 01/2014, Volume 33, Issue 5, pp. 539 - 549
Aurora kinase A (AURKA) localizes to centrosomes and mitotic spindles where it mediates mitotic progression and chromosomal stability. Overexpression of AURKA... 
migration | adhesion | ovarian cancer | SRC | Aurora kinase A | alisertib | SUPPRESSES TUMOR-GROWTH | ACTIVATION | METASTASIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | ANTITUMOR-ACTIVITY | SMALL-MOLECULE INHIBITOR | CELL BIOLOGY | OVEREXPRESSION | ONCOLOGY | IN-VIVO | GENETICS & HEREDITY | A KINASE | CARCINOMA | EXPRESSION | Neoplasm Transplantation | RNA, Small Interfering - genetics | Phosphorylation | Paclitaxel - pharmacology | Apoptosis - drug effects | Humans | Ovarian Neoplasms - pathology | Apoptosis - genetics | Aurora Kinase A - antagonists & inhibitors | Aurora Kinase A - metabolism | Neoplasm Metastasis | RNA Interference | src-Family Kinases - metabolism | Female | Aurora Kinase A - genetics | Neoplasms, Glandular and Epithelial - pathology | Pyrimidines - pharmacology | Cell Adhesion | Ovarian Neoplasms - enzymology | Azepines - pharmacology | Neoplasms, Glandular and Epithelial - enzymology | Xenograft Model Antitumor Assays | Animals | Mitosis - drug effects | Cell Cycle Checkpoints - drug effects | Carcinoma, Ovarian Epithelial | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Antineoplastic Agents, Phytogenic - pharmacology | Cell Movement | Oncology, Experimental | Physiological aspects | Development and progression | Metastasis | Research | Epithelium | Phosphotransferases | Ovarian cancer | Cancer | Studies | Oncology | Cell adhesion & migration
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2016, Volume 34, Issue 4_suppl, pp. 504 - 504
Journal Article
International Journal of Gynecological Cancer, ISSN 1048-891X, 07/2009, Volume 19, Issue 5, pp. 929 - 933
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2011, Volume 123, Issue 1, pp. 19 - 26
Abstract Objective Patients with persistent/recurrent epithelial ovarian cancer/primary peritoneal cancer (EOC/PPC) have limited treatment options. AKT and... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | mTOR inhibitor | Circulating tumor cells | Ovarian clinical trial | AKT/PI3K pathway | MAMMALIAN TARGET | CARCINOMA PATIENTS | REFRACTORY OVARIAN | PERIPHERAL-BLOOD | METASTATIC COLORECTAL-CANCER | PLATINUM-RESISTANT | OBSTETRICS & GYNECOLOGY | BREAST-CANCER | ONCOLOGY | THERAPEUTIC TARGET | RESISTANT PROSTATE-CANCER | DISEASE PROGRESSION | TOR Serine-Threonine Kinases - metabolism | Peritoneal Neoplasms - blood | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasms, Glandular and Epithelial - metabolism | Antineoplastic Agents - therapeutic use | TOR Serine-Threonine Kinases - antagonists & inhibitors | Young Adult | Neoplasms, Glandular and Epithelial - blood | Peritoneal Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Ovarian Neoplasms - metabolism | Proto-Oncogene Proteins c-akt - metabolism | Ovarian Neoplasms - drug therapy | Sirolimus - adverse effects | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Neoplastic Cells, Circulating - drug effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Ovarian Neoplasms - blood | Cyclin D1 - biosynthesis | Disease-Free Survival | Peritoneal Neoplasms - metabolism | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Aged | Antimitotic agents | Relapse | Care and treatment | Clinical trials | Product development | Metastasis | Antineoplastic agents | Diseases | Cancer | Index Medicus | PI3K pathway | AKT | ovarian clinical trial
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.